Announcement PDF Avecho Biotechnology Limited | ASX:AVE | ACN: 056 482 403 | ABN: 32 056 482 403 Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168 avecho.com.au ASX Announcement 26 May 2026 2026 Annual General Meeting Results Melbourne, Australia, 26 May 2026 – In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), Avecho Biotechnology Limited (ASX: AVE) advises that the details of the resolutions and the proxies received in respect of each resolution at its Annual General Meeting today are set out in the attached proxy summary. For enquiries, please contact Naomi Lawrie Company Secretary +61 1300 384 692 This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited. About Avecho Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients. Avecho’s lead asset is a proprietary cannabidiol (“CBD”) TPM soft-gel capsule demonstrated to increase CBD absorption. The CBD soft-gel capsule is currently undergoing Phase III clinical development for the treatment of insomnia. See more here - avecho.com.au Resolution Result Resolution Resolution Type For Against Proxy's Discretion Abstain For Abstain* Carried / Not Carried 1,187,473,648 26,869,297 13,179,918 3,513,727 1,240,030,875 3,513,727 Carried 96.74% 2.19% 1.07% 97.88% 1,188,484,836 26,096,665 13,178,807 19,793,789 1,240,840,952 19,793,789 Carried 96.80% 2.13% 1.07% 97.92% 1,103,464,777 23,726,771 13,363,807 3,832,075 1,179,095,558 3,832,075 Carried 96.75% 2.08% 1.17% 98.02% 1,139,016,466 36,970,098 13,363,807 64,037,059 1,214,524,247 64,037,059 Carried 95.77% 3.11% 1.12% 97.03% 1,211,907,522 23,746,128 13,363,807 4,369,973 1,287,415,303 4,369,973 Carried 97.03% 1.90% 1.07% 98.17% Resolution Reasons(s) for not putting resolution to the meeting 2 Re-Election of Mr Matthew Patrick McNamara as a Director of the Company Refer to ASX Announcement dated 25 May 2026 Withdrawn This resolution was withdrawn 6 Approval of 10% Placement Facility Special 23,946,128 1.83% * Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. 4 Ratification of prior Issue of 182,653,633 Shares under Placement Ordinary 23,803,771 1.98% 5 Ratification of prior Issue of 20,000,000 Options to the Lead Manager (or its nominee) Ordinary 37,170,098 2.97% 2 Re-Election of Mr Matthew Patrick McNamara as a Director of the Company Ordinary 3 Renewal of Avecho Biotechnology Limited Equity Incentive Plan Ordinary 26,296,665 2.08% This resolution was withdrawn Against 1 Adoption of Remuneration Report Ordinary 26,869,297 2.12% Resolution details Instructions given to validly appointed proxies Number of votes cast on the poll (as at proxy close) (where applicable) Avecho Biotechnology Limited Annual General Meeting Tuesday, 26 May 2026 Results of Meeting The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2. 1/1